100 related articles for article (PubMed ID: 18382904)
1. Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle-stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients.
Martínez F; Clua E; Parera N; Rodríguez I; Boada M; Coroleu B
Gynecol Endocrinol; 2008 Apr; 24(4):188-93. PubMed ID: 18382904
[TBL] [Abstract][Full Text] [Related]
2. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
3. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
Barmat LI; Chantilis SJ; Hurst BS; Dickey RP
Fertil Steril; 2005 Feb; 83(2):321-30. PubMed ID: 15705369
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
[TBL] [Abstract][Full Text] [Related]
5. [Clinical applications of different doses of leuprorelin acetate in in vitro fertilization-embryo transfer].
Wang L; Zhang WX; Jiang H
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):910-4. PubMed ID: 23324190
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation.
Fluker M; Grifo J; Leader A; Levy M; Meldrum D; Muasher SJ; Rinehart J; Rosenwaks Z; Scott RT; Schoolcraft W; Shapiro DB;
Fertil Steril; 2001 Jan; 75(1):38-45. PubMed ID: 11163814
[TBL] [Abstract][Full Text] [Related]
7. What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders?
Berkkanoglu M; Ozgur K
Fertil Steril; 2010 Jul; 94(2):662-5. PubMed ID: 19368912
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
9. Randomized, comparative pilot study of pituitary suppression with depot leuprorelin versus cetrorelix acetate 3 mg in gonadotropin stimulation protocols for oocyte donors.
Martínez F; Clua E; Santmartí P; Boada M; Rodriguez I; Coroleu B
Fertil Steril; 2010 Nov; 94(6):2433-6. PubMed ID: 20430379
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone.
Moon SY; Ku SY; Kim SM; Jee BC; Suh CS; Choi YM; Kim JG; Kim SH
J Obstet Gynaecol Res; 2005 Jun; 31(3):227-35. PubMed ID: 15916659
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
Cheon KW; Byun HK; Yang KM; Song IO; Choi KH; Yoo KJ
J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
[TBL] [Abstract][Full Text] [Related]
12. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
Fatemi HM; Doody K; Griesinger G; Witjes H; Mannaerts B
Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
[TBL] [Abstract][Full Text] [Related]
13. [A randomized, controlled trial comparing follicle stimulating hormone (FSH) to human menopausal gonadotropin (hMG) in fertilization in vitro].
Daya S; Gumby J; Hughes EG; Collins JA; Sagle MA
Contracept Fertil Sex; 1995 Dec; 23(12):766-71. PubMed ID: 8556078
[TBL] [Abstract][Full Text] [Related]
14. GnRH antagonist in older IVF patients. Retrieval rates and clinical outcome.
Chang PL; Zeitoun KM; Chan LK; Thornton MH; Sauer MV
J Reprod Med; 2002 Apr; 47(4):253-8. PubMed ID: 12012875
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.
Hompes PG; Broekmans FJ; Hoozemans DA; Schats R;
Fertil Steril; 2008 Jun; 89(6):1685-93. PubMed ID: 17681325
[TBL] [Abstract][Full Text] [Related]
16. Impact of recombinant follicle-stimulating hormone and human menopausal gonadotropins on in vitro fertilization outcome.
Strehler E; Abt M; El-Danasouri I; De Santo M; Sterzik K
Fertil Steril; 2001 Feb; 75(2):332-6. PubMed ID: 11172835
[TBL] [Abstract][Full Text] [Related]
17. Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin.
Requena A; Cruz M; Ruiz FJ; García-Velasco JA
Reprod Biol Endocrinol; 2014 Jan; 12():10. PubMed ID: 24476504
[TBL] [Abstract][Full Text] [Related]
18. An oocyte donation protocol using the GnRH antagonist ganirelix acetate, does not compromise embryo quality and is associated with high pregnancy rates.
Vlahos NF; Bankowski BJ; Zacur HA; Garcia JE; Wallach EE; Zhao Y
Arch Gynecol Obstet; 2005 Jun; 272(1):1-6. PubMed ID: 15838696
[TBL] [Abstract][Full Text] [Related]
19. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
20. Advantages of recombinant follicle-stimulating hormone over human menopausal gonadotropin for ovarian stimulation in intrauterine insemination: a randomized clinical trial in unexplained infertility.
Rashidi M; Aaleyasin A; Aghahosseini M; Loloi S; Kokab A; Najmi Z
Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(2):244-7. PubMed ID: 23541417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
